Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1786 • ACR Convergence 2024
Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Christian Wright¹, Rufei Lu², Catriona Wagner³, Carla Guthridge⁴, Susan Macwana¹, Eliza Chakravarty⁴, Tammy Utset⁵, Diane Kamen⁶, Gabriel Nicolas Contreras Martin⁷, William McCune⁸, Cynthia Aranow⁹, Kenneth Kalunian¹⁰, Elena Massarotti¹¹, Megan Clowse¹², Brad Rovin¹³, S. Sam Lim¹⁴, Vikas Majithia¹⁵, Richard Looney¹⁶, Maria Dall'Era¹⁷, Doruk Erkan¹⁸, Amit Saxena¹⁹, Nancy Olsen²⁰, Kichul Ko²¹, Ellen Goldmuntz²², William Barry²³, Ashley Pinckney²⁴, ALE06 Clinical Study Team⁴, Judith James⁴ and Joel Guthridge⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²University of California San Francisco, San Bruno, CA, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Chicago, Chicago, IL, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Miami, Key Biscayne, FL, ⁸U Michigan, Ann Arbor, MI, ⁹Feinstein Institutes for Medical Research, New York, NY, ¹⁰University of California San Diego, La Jolla, CA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Duke University, Chapel Hill, NC, ¹³The Ohio State University, Columbus, OH, ¹⁴Emory University, Atlanta, GA, ¹⁵Mayo Clinic Florida, Jacksonville, FL, ¹⁶University of Rochester, Rochester, NY, ¹⁷UCSF, Corte Madera, CA, ¹⁸Hospital for Special Surgery, New York, NY, ¹⁹NYU School of Medicine, New York, NY, ²⁰Penn State University/Milton S Hershey, Hershey, PA, ²¹The University of Chicago, Chicago, IL, ²²NIAID/ NIH, Washington, DC, ²³Rho, Inc, Durham, NC, ²⁴Rho, St Louis Park, NC
Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
Abstract Number: 2266 • ACR Convergence 2024
Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Fenglong Xie⁶, Joshua Baker¹ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Patients with RA are at increased risk of serious infection, but less is known about common, non-serious infections. Our prospective study aimed to assess…
Abstract Number: 0259 • ACR Convergence 2024
Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series
Judith den Hertog¹, Maike Wientjes¹, Jaap ten Oever², Merel Opdam¹, Denise Telgt¹ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Radboudumc, Nijmegen, Netherlands
Background/Purpose: Whipple’s disease is a presumably rare, chronic infectious disease caused by the bacterium Tropheryma whipplei. Symptoms include weight loss, diarrhea, abdominal discomfort, joint pain…
Abstract Number: 0519 • ACR Convergence 2024
Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers
Ming‑Han Chen¹, Mao-Yuan Chen², Shih-Hsin Chang³ and DER-YUAN CHEN⁴, ¹Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan, ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ³Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China), ⁴heumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: JAK inhibitors (JAKi) and biologic disease-modifying antirheumatic drugs (bDMARDs) have proven efficacy in the treatment of rheumatoid arthritis (RA). However, their potential for increasing…
Abstract Number: 0883 • ACR Convergence 2024
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Jorge Monserrat¹, Cristina Bohorquez², Ana Maria Gómez³, Elena Rabadán Rubio⁴, Raquel Sánchez³, Atusa Movasat⁵, Lucia Ruiz⁴, Fernando Albarran Hernandez⁶, Miguel Ángel Ortega¹, Ana Perez⁶ and Melchor Alvarez-Mon⁷, ¹Universidad de Alcalá. IRYCIS, Alcalá de Henares, Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ³Universidad de Alcalá, Alcalá de Henares, Madrid, Spain, ⁴Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁶Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁷Universidad de Alcalá. HUPA. IRYCIS, Madrid, Spain

Background/Purpose: Rheumatoid arthritis (RA) is a highly inflammatory severe chronic autoimmune disorder with an inadequate activation of the immune cells. These cells are responsible for…
Abstract Number: 1368 • ACR Convergence 2024
Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
Prabhu Vasanth¹, John Mathew² and Divya K³, ¹Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, India, ³Christian Medical College, Vellore, Tamil Nadu, India
Background/Purpose: Conventional synthetic DMARDs remained the mainstay of treatment of RA for decades. However, their use has decreased recently due to the emergence of biological…
Abstract Number: 1479 • ACR Convergence 2024
Effectiveness of B/tsDMARDs Including Ixekizumab Per Line of Therapy and Concomitant CsDMARDs in Psoriatic Arthritis: Real-World Data from a Prospective Observational Study
Philipp Sewerin¹, Nicola Gullick², Hagen Russ³, Khai Jing Ng⁴, meadhbh O’Neill⁵, Sebastián Moyano⁶, Federica Giurdanella⁵, Adela Gallego- Flores⁷ and Francesco Ciccia⁸, ¹Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ²University Hospitals Coventry & Warwickshire NHS trust, Warwickshire, United Kingdom, ³Eli Lilly, Indianopolis, ⁴Eli Lilly and Company, Madrid, Spain, ⁵Eli Lilly, Indianopolis, IN, ⁶Eli Lilly and Company, Alcobendas, Spain, ⁷Hospital Perpetuo Socorro, Badajoz, Spain, ⁸Università degli studi della Campania Luigi Vanvitelli, Naples, Italy
Background/Purpose: Treatment (tx) guidelines for PsA recommend biologic DMARDs (bDMARDs) or targeted synthetic (ts) DMARDs after inadequate response to conventional synthetic DMARDs (csDMARDs)1. In clinical…
Abstract Number: 1843 • ACR Convergence 2024
Immune Responses to Herpes Zoster Vaccine Responses in Rheumatic Patients on JAK Inhibitors: Insights in Humoral and Cellular Response
cristiana sieiro santos¹, Juan Garcia Herrero², Jose Ordas Martínez³, Alejandra López Robles⁴, Carolina Álvarez Castro⁴, Ronald Colindres⁴, Estefanía Robles Martin⁴, Ana María Sahagún⁵ and Jose María Ruiz de Morales⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵University of Leon, León, Spain
Background/Purpose: Patients with immune-mediated rheumatic diseases treated with JAK inhibitors face an elevated risk of herpes zoster (HZ) infection. Shingrix, a recombinant inactive vaccine, offers…
Abstract Number: 2272 • ACR Convergence 2024
Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry
Dimitrios Pappas¹, George Reed², Kevin kane³, Michael Weinblatt⁴ and Joel Kremer⁵, ¹CorEvitas, New York, NY, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Massachusetts Lowell, Lowell, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Methotrexate (MTX) continues to be the cornerstone therapy in the treatment of rheumatoid arthritis (RA) and is usually the first conventional synthetic (cs) DMARD…
Abstract Number: 0295 • ACR Convergence 2024
Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Namitha Nair¹, Leen Al Saleh², Haya Haddad³, Maria Jaimes Reyes⁴, Vishakha Chetram⁵, Farooq Sheikh⁶, FLORINA CONSTANTINESCU⁷ and Anjani Pillarisetty⁸, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Watson Clinic, Lakeland, FL, ³Medstar Washington Hospital Center, Silver Spring, MD, ⁴Medstar Washington Hospital Center/Georgetown University, Washington, DC, ⁵Inova Schar Heart and Vascular, Falls Chirch, VA, ⁶MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, ⁷MedStar Washington Hospital Center, Washington, DC, ⁸Carson Tahoe Medical Group, Reno, NV
Background/Purpose: Cardiac involvement is seen in approximately a fourth of patients with sarcoidosis, a non-necrotizing granulomatous systemic disease. Among these patients, 25% may have isolated cardiac…
Abstract Number: 0520 • ACR Convergence 2024
Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study
Yoichi Nakayama¹, Daijiro Kabata², Wataru Yamamoto³, Hidehiko Makino⁴, Koji Nagai⁴, Naofumi Yoshida⁵, Yonsu Son⁵, Masaki Katayama⁶, Hirotaka Yamada⁷, Keisuke Nishimura⁷, Ryota Hara⁸, Ryu Watanabe⁹, Yuki Etani¹⁰, Kosuke Ebina¹¹, Hideo Onizawa¹², Takayuki Fujii¹³, Akira Onishi¹⁴, Kosaku Murakami¹⁵, Koichi Murata¹², Masao Tanaka¹⁴, Shuichi Matsuda¹², Akio Morinobu¹⁶, Ayumi Shintani² and Motomu Hashimoto⁹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Okayama, Japan, ⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁵First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan, ⁶Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, ⁸Department of Orthopaedic Surgery, Nara Medical University, Nara, Nara, Japan, ⁹Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ¹⁰Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹¹Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ¹³Kyoto University, Kyoto, Japan, ¹⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: A delay in initiating disease-modifying antirheumatic drugs (DMARDs) has been linked to poor outcomes in patients with rheumatoid arthritis (RA). Several studies have implicated…
Abstract Number: 0886 • ACR Convergence 2024
A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis
Chenxi Zhu¹, Siyu He², Yi Liu³, Rui Sun¹ and Yi Zhao⁴, ¹Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), ²West China Hospital Sichuan University, chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, ⁴Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a complex systemic inflammatory autoimmune disease with a high incidence, primarily affecting the joints. However, it currently lacks definitive biomarkers…
Abstract Number: 1369 • ACR Convergence 2024
Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
Peter Youssef¹, Sabina Ciciriello², Talib Tahir³, Tegan Smith⁴, Catherine O'Sullivan⁴, Joanna Leadbetter⁵, Belinda Butcher⁵, Nicole Walsh⁶, Miriam Calao⁶ and Geoffrey Littlejohn⁷, ¹Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, ²The University of Melbourne, Melbourne, Victoria, Australia, ³Coburg Rheumatology Service, Coburg, Victoria, Australia, ⁴OPAL Rheumatology Ltd, Geelong, Victoria, Australia, ⁵WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁶AbbVie Pty Ltd, Mascot, New South Wales, Australia, ⁷Monash University, Clayton, Victoria, Australia
Background/Purpose: To describe the real-world treatment patterns, response and persistence in rheumatoid arthritis (RA) patients (pts) treated with upadacitinib (UPA).Methods: This retrospective, non-interventional, multicenter cohort…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…
Abstract Number: 1893 • ACR Convergence 2024
Hydroxychloroquine Use in Early Pregnancy and Risk of Preterm Delivery in a Californian Cohort of Lupus Pregnancy
Amadeia Rector¹, Emily Liu², Miranda Cantu³, Eliza Chakravarty⁴, Maurice Druzin⁵, Gary Shaw⁶, Michael Weisman⁷, Monique Hedderson² and Julia Simard⁸, ¹Stanford University, San Francisco, CA, ²Kaiser Permanente Division of Research, Oakland, CA, ³Patient partner, Portage, MI, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Stanford University School of Medicine, Stanford, ⁷Stanford University, Los Angeles, CA, ⁸Stanford School of Medicine, Stanford, CA
Background/Purpose: Preterm delivery (PTD) occurs 2-3 times more frequently in patients with systemic lupus erythematosus (SLE) compared to the general obstetric population. Hydroxychloroquine (HCQ), a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].